A new study by scientists at the CSIR-Centre for Cellular and Molecular Biology (CCMB) in Hyderabad has revealed how viral ...

The study, published in ‘Cell Reports’, examined how RNA viruses interact with a protein named alpha-synuclein, that forms ...

At the time, it was the longest Olympic torch relay in the U.S., an epic buildup for Atlanta, the first American city in the ...

Hyderabad’s CCMB has identified how viral RNA structures may accelerate α-synuclein amyloid formation linked to Parkinson’s ...

A CCMB study has identified how RNA viruses may trigger alpha-synuclein aggregation linked to Parkinson’s disease and how the ...

But a bout of flu doesn’t always end after the coughing, fever and runny nose. Some people may develop “long flu,” with ...

AbbVie (ABBV) just secured U.S. FDA approval for JUVMO, a Parkinson's disease pill that targets D1/D5 receptors. This gives ...

Gain Therapeutics’ lead drug candidate rexaceract, formerly known as GT-02287, is in clinical development for the treatment ...

People living with Parkinson’s disease are hospitalized more often than other older adults, most often because of infections, falls, fractures, or other medical problems rather than Parkinson’s itself ...

A Northeastern student’s co-op at Mass General Hospital is helping researchers understand the rare, fatal illness called ...

AbbVie stock (ABBV) slipped slightly on Monday, down 0.29%, after the company announced a major regulatory win. The FDA ...

JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients ...